|
|
|
|
Progenics Announces Fourth Quarter and Year-End 2009 Financial Results
TARRYTOWN, N.Y.-- (BUSINESS WIRE) -- Progenics Pharmaceuticals, Inc.(Nasdaq: PGNX) today announced its results of operations for the fourth quarter and year ended December 31, 2009. Financial Results Net loss for the fourth quarter was $0.6 million or $0...
|
|
|
Progenics Announces Fourth Quarter and Year-End 2009 Financial Results
TARRYTOWN, N.Y.--(BUSINESS WIRE)--Progenics Pharmaceuticals, Inc.(Nasdaq: PGNX) today announced its results of operations for the fourth quarter and year ended December 31, 2009. Net loss for the fourth quarter was $0.6 million or $0.02, basic and diluted,...
|
|
|
Progenics reports narrowed 4Q loss, revenue rise
Biopharmaceutical company Progenics Pharmaceuticals Inc.said Monday its fourth-quarter loss narrowed, as revenue spiked due to a payment from Wyeth, which ended a collaboration between the companies. The Tarrytown, N.Y., company said it lost $639,000, or 2...
|
|
|
Progenics Pharma reports narrowed 4th-quarter loss as revenue rises on Wyeth payment
TARRYTOWN, N.Y.Biopharmaceutical company Progenics Pharmaceuticals Inc. said Monday its fourth-quarter loss narrowed, as revenue spiked due to a payment from Wyeth, which ended a collaboration between the companies. The Tarrytown, N.Y., company said it...
|
|
|
Progenics Announces Fourth Quarter and Year-End 2009 Financial Results
Financial Results Net loss for the fourth quarter was $0.6 million or $0.02, basic and diluted, per share, compared to $14.6 million or $0.48, basic and diluted, per share in the fourth quarter of 2008.Net loss for the year was $30.6 million or $0.98, basic...
|
|
|
Progenics Announces Fourth Quarter and Year-End 2009 Financial Results
- Progenics Pharmaceuticals, Inc.(Nasdaq: PGNX) today announced its results of operations for the fourth quarter and year ended December 31, 2009. Financial Results Net loss for the fourth quarter was $0.6 million or $0.02, basic and diluted, per share,...
|
|
|
Progenics says oral Relistor met goal in study
TARRYTOWN, N.Y.-- Progenics Pharmaceuticals Inc. said Friday that an oral version of its constipation drug Relistor met its goal in a clinical trial, and the company plans further trials of the drug. Relistor is designed to treat constipation...
|
|
|
Progenics says oral Relistor met goal in study
Progenics Pharmaceuticals Inc.said Friday that an oral version of its constipation drug Relistor met its goal in a clinical trial, and the company plans further trials of the drug. Relistor is designed to treat constipation caused by use of...
|
|
|
Ono Pharmaceutical Co., Ltd. - Pharmaceuticals & Healthcare - Deals and Alliances Profile - new market report released
Refer to a friend 2010-03-10 14:15:02 - Ono Pharmaceutical Co., Ltd.- Pharmaceuticals & Healthcare - Deals and Alliances Profile - a new market research report on companiesandmarkets.com Ono Pharmaceutical Co., Ltd. - Pharmaceuticals & Healthcare -...
|
|
|
Progenics Pharmaceuticals, Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile - new market
www.companiesandmarkets.com/Summary-Company-Profile/progenics-ph ..Progenics Pharmaceuticals, Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile is an essential source for company data and information. The profile examines the companys...
|
|
|
Company Financials: Progenics Pharmaceuticals, Inc. - new market report released
Refer to a friend 2010-03-08 21:55:12 - Company Financials: Progenics Pharmaceuticals, Inc.- a new market research report on companiesandmarkets.com The Company Financials offers insights into the financial performance of the company over last five years for...
|
|
|
Progenics Pharmaceuticals, Inc. - Financial And Strategic Analysis Review - New Report Published
Newly released report, Progenics Pharmaceuticals, Inc.- Financial and Strategic Analysis Review, provides detailed company analysis Published on February 11, 2010by Press Office(Companiesandmarkets.com and OfficialWire)LONDON, ENGLAND Progenics...
|
|
|
Morphine may accelerate cancer growth, research suggests
A U.S.researcher said several studies have begun to show that opiate-based pain drugs stimulate cancer cell growth and foster the spread of cancers. A key study in 2002 showed that cancer patients who were given morphine delivered to the spine, rather than...
|
